Collegium Pharmaceutical (COLL) News Today $33.35 -0.11 (-0.33%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Burney Co. Sells 38,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Burney Co. cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 34,476 shares of the specialty pharmaceutical company's stock after selling 38,157 shares during thJanuary 17 at 4:31 AM | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells $908,600.00 in StockJanuary 15 at 4:41 AM | insidertrades.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann Sells 27,500 SharesCollegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 27,500 shares of the company's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 14, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy ratJanuary 13, 2025 | marketbeat.comJPMorgan Chase & Co. Has $10.71 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 173.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 277,204 shares of the specialty pharmaceutical company's stock after buying anJanuary 13, 2025 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Upgraded at Needham & Company LLCJanuary 13, 2025 | americanbankingnews.comCollegium Pharmaceutical's (COLL) Buy Rating Reaffirmed at HC WainwrightJanuary 12, 2025 | americanbankingnews.comNeedham Upgrades Collegium Pharmaceutical (COLL)January 10, 2025 | msn.comCollegium Pharmaceutical’s Promising Growth and Undervalued Potential: A Buy Rating by Serge BelangerJanuary 10, 2025 | markets.businessinsider.comCollegium Pharmaceutical upgraded to Buy from Hold at NeedhamJanuary 10, 2025 | markets.businessinsider.comCollegium Pharmaceutical's (COLL) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday.January 10, 2025 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by Needham & Company LLCNeedham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a report on Friday.January 10, 2025 | marketbeat.comCollegium Pharmaceutical sees FY25 revenue $735M-$750M, consensus $739.84MJanuary 8, 2025 | markets.businessinsider.comCollegium Pharmaceutical (NASDAQ:COLL) Trading Up 2.8% - What's Next?Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Up 2.8% - Still a Buy?January 8, 2025 | marketbeat.comCollegium Provides 2025 Financial Guidance and Business UpdateJanuary 8, 2025 | globenewswire.comCollegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month Low - Here's What HappenedCollegium Pharmaceutical (NASDAQ:COLL) Reaches New 52-Week Low - Here's WhyJanuary 7, 2025 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low - Should You Sell?Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year Low - What's Next?December 30, 2024 | marketbeat.comPulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focusDecember 25, 2024 | finance.yahoo.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Barclays PLCBarclays PLC raised its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 152.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 75,052 shares of the speDecember 25, 2024 | marketbeat.comCollegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low - What's Next?Collegium Pharmaceutical (NASDAQ:COLL) Sets New 52-Week Low - What's Next?December 23, 2024 | marketbeat.comPrincipal Financial Group Inc. Grows Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Principal Financial Group Inc. grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 3.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,745,818 shares of the specialty pharmaceuticDecember 22, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and three have assigned aDecember 19, 2024 | marketbeat.comIndivior CFO steps down from board after discussions with Oaktree CapitalDecember 17, 2024 | msn.comWellington Management Group LLP Increases Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Wellington Management Group LLP raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 17.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,640 shares of the specialty pDecember 17, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Holdings Lifted by Fmr LLCFmr LLC raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1,532.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,752 shares of the specialty pharmaceutical company's stock after buying an additDecember 16, 2024 | marketbeat.comJanus Henderson Group PLC Buys 55,572 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Janus Henderson Group PLC increased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 399.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 69,485 shares of the specialty pharmaceutical company's stock afterDecember 12, 2024 | marketbeat.comLoomis Sayles & Co. L P Has $737,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Loomis Sayles & Co. L P lessened its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 90.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,075 shares of the specialty pharmaceuticalNovember 28, 2024 | marketbeat.comPenserra Capital Management LLC Invests $757,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Penserra Capital Management LLC purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,600 shares of the specialty pharmaceuticaNovember 28, 2024 | marketbeat.comRubric Capital Management LP Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Rubric Capital Management LP trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 46.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,250,000 shares of thNovember 27, 2024 | marketbeat.comCollegium Pharmaceutical: Strong Growth With Pain Management And ADHD ExpansionNovember 26, 2024 | seekingalpha.comMassachusetts Financial Services Co. MA Boosts Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 17.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 765,692 shares of the specialty pharNovember 26, 2024 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and thNovember 24, 2024 | marketbeat.comPacer Advisors Inc. Trims Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Pacer Advisors Inc. cut its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 24.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,589,648 shares of the specialty pharmaceutical compNovember 22, 2024 | marketbeat.com121,446 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Bought by Empowered Funds LLCEmpowered Funds LLC bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 121,446 shares of the specialty pharmaceuticNovember 18, 2024 | marketbeat.comVictory Capital Management Inc. Has $27.46 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Victory Capital Management Inc. grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 43.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 710,688 shares of the specialty pharmaceutical company'sNovember 18, 2024 | marketbeat.comCollegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings SuggestNovember 14, 2024 | finance.yahoo.comKnight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)November 14, 2024 | globenewswire.comCollegium to Participate in Upcoming Investor ConferencesNovember 13, 2024 | finance.yahoo.comMeritage Portfolio Management Purchases Shares of 19,776 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Meritage Portfolio Management bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 19,776 shares of the specialty pharmaceutical company's stock, valuedNovember 11, 2024 | marketbeat.comPrincipal Financial Group Inc. Buys 64,958 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Principal Financial Group Inc. increased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 3.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,745,818 shares of the specialty pharmaceutical comNovember 10, 2024 | marketbeat.comCollegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2024 | finance.yahoo.comCollegium Pharmaceutical: Hold Rating Amid Uncertainty Despite Strong Q3 PerformanceNovember 9, 2024 | markets.businessinsider.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comRobeco Institutional Asset Management B.V. Has $4.44 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)Robeco Institutional Asset Management B.V. boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 265.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 114,965 shares of the specialty phaNovember 9, 2024 | marketbeat.comCollegium Pharmaceutical Reports Strong Q3 2024 ResultsNovember 8, 2024 | markets.businessinsider.comCollegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comCollegium Pharmaceutical appoints Vikram Karnani as CEONovember 8, 2024 | markets.businessinsider.comCollegium Pharmaceutical, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 7, 2024 | seekingalpha.comPiper Sandler Remains a Hold on Pacira Pharmaceuticals (PCRX)November 7, 2024 | markets.businessinsider.comCollegium Pharmaceutical Taps Vikram Karnani as CEONovember 7, 2024 | marketwatch.com Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Media Mentions By Week COLL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COLL News Sentiment▼0.730.57▲Average Medical News Sentiment COLL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COLL Articles This Week▼84▲COLL Articles Average Week Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VKTX News Today AXSM News Today KRYS News Today TGTX News Today OGN News Today SRRK News Today ALVO News Today RARE News Today ADMA News Today BHVN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COLL) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COLL Stock Alerts